• SQZ Biotechnologies intends to raise $75 million in an IPO of its common stock.
• The firm is researching treatments for HPV+ solid tumors and other conditions using its 'Cell Squeeze' approach.
• SQZ has had promising results in early trials, has a significant collaboration with Roche and the IPO appears reasonably priced, so is worth a close look.
• Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »

Quick Take

SQZ Biotechnologies Company (SQZ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement.

The company is a clinical stage biopharma developing treatments for cancer, infectious diseases and diabetes.

SQZ has produced promising trial results, has a strong collaboration deal with Roche, ample resources and reasonable IPO valuation.

For life science investors with an 18 to 24-month hold time frame, the IPO is worth consideration.

Company & Technology

Watertown, Massachusetts-based SQZ was founded to develop its Cell Squeeze technology that squeezes cells 'through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell.'

Management is headed by founder and CEO Armon Sharei, Ph.D., who is the inventor of the core technology of the company.